Skip to main content

Table 1 Patients’ characteristics at time of administration of IMM-101

From: Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity

  Patient 1 Patient 2 Patient 3 Patient 4
M1 stage AJCC v.8 M1a (0) M1c (1) M1c (0) M1b (0)
Baseline LDH Normal Abnormal Abnormal Normal
BRAF status Wild-type Wild-type Wild-type Wild-type
Number of metastases 6 > 10 > 10 5
Sites of metastases Subcutaneous Lung, peritoneum, stomach, nodes Lung, subcutaneous, nodes, adrenal Lung, subcutaneous